Sanjay Popat

YouTube video by IASLC IASLC 2026 IASLC Targeted Therapies of Lung Cancer: Special Presentation by Dr. Ross Camidge

One of the most touching, moving, sad (at times), funny (if that’s possible) & above all thoughtful talks about such a personal matter.
Truly humbled when listening. Ross, you always teach us something news. Sage words, forever lessons.
@iaslc.bsky.social @btog.bsky.social

youtu.be/cnh579D04QI?...

Hiding in Plain Sight: The Neuro-Protective Benefit of Tyrosine Kinase Inhibition in Non–Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers

www.sciencedirect.com/science/arti... Now in press in Journal of Thoracic Oncology - a hypothesis I’ve presented at meetings for a couple of years but never put in writing before.

Pleased to publish a case report exploring a number of interesting elements of ERBB2 (HER2) mutated NSCLC on @jtoonline.bsky.social with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social
www.jtocrr.org/article/S266...

Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer - PubMed Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been standard of care as monotherapy for EGFR-mutated advanced non-small cell lung cancer since reporting of the FLAURA phase III clinical trial, which demonstrated superiority over first-generatio …

pubmed.ncbi.nlm.nih.gov/41609978/
Delighted to explore the complex landscape of EGFRm NSCLC in 2026 with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social

Mechanisms of resistance
FLAURA vs MARIPOSA vs FLAURA 2
Decision making after these regimens
Genomic informed and agnostic approaches

There’s a lot going on and new in #lungcancer. Be there to understand the latest developments!

Cat Cafe?! I never knew such a thing existed. How wonderful.

Fellows, writing a manuscript with me? The 10 golden rules never grow old

For those of you wondering why newer antibodies are now called -tugs -barts -migs and -ments not -mabs, this is the official @who.int INN explainer

tinyurl.com/49bxfn4t

🌍 Why do people who’ve never smoked get lung cancer?
Our first session dives into epidemiology, environmental aetiology, and early detection.
With @ruthstraussfdn.bsky.social‬
🧠 #BTOG2025 | 📍 London | 📅 13 Nov
🔗 www.btog.org/non-smo...
#LungCancer #LCSM #NonSmokingLungCancer

The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸

@biagioricciutimd.bsky.social
‬ @stephenvliu.bsky.social
@drsanjaypopat.bsky.social
Ping
@drjnaidoo.bsky.social

Thank you #LCS2025 in #KualaLumpur 🇲🇾 for hosting an informative & interactive lung cancer meeting! Always pleasure to meet colleagues who are keen to move our 🫁 field forward. #LCSM @apoddc @APCLC_2023

@stephanieplsaw @drdaviddwlee #BeungChulAhn #PJVoon #JenniferLeong @drsanjaypopat.bsky.social

❗️FLAURA2 approved by NICE❗️

Already on BlueTeq!

Now an option for 1L EGFR+ pts

Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen

Great to see this important step for our EGFR mutant patients: FLAURA-2 approval by NICE. Interesting to note that the reimbursement (Blueteq form) allows a single cycle of chemo if clinically urgently indicated, but no access if PD on adjuvant osi. @btog.bsky.social @egfrpositiveuk.bsky.social

Very important dataset and a set forward to potential ambulatory delivery in the future.

HER2 mutated NSCLC increasingly important as a rest of new TKI show promising effectiveness in early phase trials

Riyaz Shah and I discuss these, and other HER2 targeted treatments

Dose optimisation to improve access to effective cancer medicines Access to many cancer medicines on WHO's Essential Medicines List (EML) is restricted because of price, especially in low-income and middle-income countries (LMICs). Other cancer medicines that have b...

Very nice perspective from Drs Tannock, De Vries & colleagues @pmresearch-uhn.bsky.social in @thelancetoncol.bsky.social on dose optimization for oncology drugs: an area that @nihr.bsky.social should be evaluating, IMHO @nhsengland.bsky.social @bopa.org.uk

shorturl.at/aszUO

Was really looking forward to this session and it didn't disappoint! Always find related questions the hardest to answer in clinic. Just a shame they had the graveyard slot!

@bopa.org.uk take note of the speakers, they would be great additions to annual conference agenda

#BTOG25

Well #BTOG25 that’s a wrap for 2025 from #Belfast

Thanks to @btog.bsky.social for 3 fantastic years in Belfast

It’s been an absolute pleasure to have the BTOG community over with us for the last 3 years 🙏

Here’s to next year in Edinburgh!
@drsanjaypopat.bsky.social
@tnewsomdavis.bsky.social

With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25

Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social!

@btog.bsky.social #BTOG25

@annaminchom.bsky.social on newer small cell therapeutic strategies and management of CRS and ICANS as specific TRAEs With thought around timings of dose delivery and education of AOS teams and patients, safely deliverable within the NHS

#BTOG25

Great job, team! @btog.bsky.social #BTOG25

Photo of Dr Naidoo on stage

Dr Naidoo presenting conclusions

Compares future to various movies

Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM

At #BTOG25 & I tringied by Matt’s comment on the fact that GP practices who request more chest X-rays have less stage III/IV #lungcaner disease? Read more here! www.respiratoryfutures.org.uk/features/dia...

We really need to make sure people know this!! It’s never too late to quit smoking. Treating tobacco dependence is cancer treatment! We would not let this survival benefit pass us by of this was a new oncology drug. #BTOG25

So what's the point in quitting smoking once you've already been diagnosed with cancer?

Quitting in the first 6 months could add extra years to survival!

#BTOG25

@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25

@drjnaidoo.bsky.social on the limited stage small cell space and the excitement around CCRT-Durvalumab. EAMS currently open in England… #BTOG25

Small cell in never smokers. On the rise for unknow reasons and a different biology. Having recently encountered my first patient who’s a never smoker(and no alcohol or recreational drugs), with extensive stage disease this insight is fascinating @stephenvliu.bsky.social #BTOG25

@drsanjaypopat.bsky.social ! The OG!!! #BTOG25 @btog.bsky.social